DRUG-INDUCED GALLBLADDER-DISEASE - INCIDENCE, ETIOLOGY AND MANAGEMENT

被引:29
作者
MICHIELSEN, PP
FIERENS, H
VANMAERCKE, YM
机构
[1] Division of Gastroenterology, University Hospital of Antwerp, Edegem, B 2650
关键词
D O I
10.2165/00002018-199207010-00005
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
A great variety of drugs is reported to induce gallbladder disease by various pathogenetic mechanisms. Early epidemiological studies indicated a doubled risk of gallbladder disease in women taking oral contraceptives. More recent studies, however, have failed to confirm those findings; these conflicting results might be explained by the different methods used to define gallbladder disease. It was shown that the lithogenic index of the bile is increased during intake of oral contraceptives. Estrogens cause hypersecretion of cholesterol in bile, due to increase in lipoprotein uptake by the hepatocyte. Progesterone inhibits acyl coenzyme A-cholesterol acyl transferase (ACAT) activity, causing delayed conversion of cholesterol to cholesterol esters. Of the lipid lowering drugs, only clofibrate has been shown to increase the risk for gallstone formation. The other fibric acid derivatives have similar properties, but clinical experience is not as extensive. They seem to be inhibitors of the ACAT enzyme system, thereby rendering bile more lithogenic. Conflicting epidemiological data exist regarding the induction of acute cholecystitis by thiazide diuretics. Ceftriaxone, a third-generation cephalosporin, is reported to induce biliary sludge in 25 to 45% of patients, an effect which is reversible after discontinuing the drug. The sludge is occasionally a clinical problem. It was clearly demonstrated that this sludge is caused by precipitation of the calcium salt of ceftriaxone excreted in the bile. Long term use of octreotide is complicated by gallstone formation in approximately 50% of patients after 1 year of therapy, due to gallbladder stasis. Hepatic artery infusion chemotherapy by implanted pump is shown to be associated with a very high risk of chemically induced cholecystitis. Prophylactic cholecystectomy at the time of pump implantation is therefore advocated. Some drugs, such as erythromcyin or ampicillin, are reported to cause hypersensitivity-induced cholecystitis. Furthermore, there are reports on the influence of cyclosporin, dapsone, anticoagulant treatment, and narcotic and anticholinergic medication in causing gallbladder disease.
引用
收藏
页码:32 / 45
页数:14
相关论文
共 113 条
[1]  
Ahrendt S.A., McGuire G.E., Pitt H.A., Lillemoe K.D., Why does somatostatin cause gallstones?, American Journal of Surgery, 161, pp. 177-183, (1991)
[2]  
Alemayehu G., Naslund I., Erytromycin orsakade leverskada och gallblaseinflammation, Läkartidningen, 87, (1990)
[3]  
Anderson A., James O.F.W., MacDonald H.A., Snowball S., Taylor W., The effect of ethynyl oesiradiol on biliary lipid composition in young men, European Journal of Clinical Investigation, 10, pp. 77-80, (1980)
[4]  
Barbara L., Sama C., Morselli Labate A.M., Taroni F., Rusticali A.G., Et al., A population study on the prevalence of gallstone disease: the Sirmione study, Hepatology, 5, pp. 913-915, (1987)
[5]  
Bennion L.J., Ginsberg R.L., Garnick M.B., Bennett P.H., Effects of oral contraceptives on the gallbladder bile of normal women, New England Journal of Medicine, 294, pp. 189-192, (1976)
[6]  
Bennion L.J., Mott D.N., Howard B.V., Oral contraceptives raise the cholesterol saturation of the bile by increasing biliary secretion, Metabolism, 29, pp. 18-22, (1980)
[7]  
Berk J.E., Management of acute cholecystitis, American Journal of Digestive Diseases, 7, pp. 325-332, (1940)
[8]  
Boden G., Shimoyama R., Somatostatinoma, Cohen & Soloway (Eds) Hormone-producing tumors of the gastrointestinal tract, pp. 85-99, (1985)
[9]  
Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumours, Lancet, 2, pp. 1399-1404, (1973)
[10]  
Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy, New England Journal of Medicine, 290, pp. 15-19, (1974)